Pharmaceutical Manufacturing (FDA/DEA) — regulation & compliance changes
Drug manufacturers and API/contract producers tracking FDA cGMP and drug-approval actions, DEA controlled-substance rescheduling and quotas, and trade actions on pharmaceutical inputs — where a cGMP finding, rescheduling, or import ruling can halt a product line.
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock so you never have to refresh a government page again. Every detected change becomes a plain-English briefing covering what changed, who it affects, what you must do, and by when. Forewarned is forearmed.
Stay ahead of every Pharmaceutical Manufacturing (FDA/DEA) change
Real-time alerts, plain-English impact briefs, and a full searchable history — 42+ changes tracked in Pharmaceutical Manufacturing (FDA/DEA) so far.
Monitor this regulation✓ No card charged during your trial · ✓ Cancel anytime · ✓ Every alert links to the official source
Recent changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Designation of Phenethyl Halides as List I Chemicals
- Whether the Food and Drug Administration Has Jurisdiction over Articles Intended for Use in Lawful Executions
- Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool’s Day Announcement - The National Law Review
- New FDA Guidance Clarifies Enforcement Discretion Policy for Certain ENDS and Nicotine Pouch Products - regulatoryoversight.com
- FDA Updates 8-Year-Old Payor Communications Guidance - The National Law Review
- FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing - Manufacturing Chemist
- FDA Releases Guidance Document on Human Factors Information in Marketing Submissions - In Compliance Magazine
- FDA drafts guidance on using next-generation sequencing to assess gene therapy safety - RAPS
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - Dykema
- FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products - Foley & Lardner LLP
- FDA cites drug firms for CGMP violations, failing to provide records - RAPS
- FDA Proposes Foreign Manufacturing Establishment Registration and Product Listing Requirements - regulatoryoversight.com
- Alito temporarily restores FDA rule allowing abortion pill mifepristone to be sent by mail - CBS News
- Modernization of Cosmetics Regulation Act of 2022 (MoCRA) - fda.gov
- FDA proposes rule to ease registration for distributed manufacturers, require foreign API sites to register - RAPS
- FDA Proposes New Registration And Listing Pathway For Distributed Drug Manufacturing And Aligns Foreign Establishment Obligations With Current Law - Mondaq
- U.S. FDA Proposes Updated Registration Framework for Distributed Drug Manufacturing - ARC Advisory Group
- US FDA proposes rule to simplify registration for some drug manufacturers - Reuters
- Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
- Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
- Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal
- Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
- Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
- Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
- Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process
- Indefinite Suspension of the De Minimis Exemption for Merchandise Arriving Through All Modes Other Than the International Postal Network
- International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availability
- Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
- Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
- Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
- Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs
Frequently asked questions
What does Aforeworn monitor for Pharmaceutical Manufacturing (FDA/DEA)?
Aforeworn continuously tracks the official rules, ordinances, fee schedules and licensing requirements that affect Pharmaceutical Manufacturing (FDA/DEA), detects every change, and explains in plain English what changed, who it hits and what to do.
How fast will I hear about a change in Pharmaceutical Manufacturing (FDA/DEA)?
Changes are detected automatically as sources update, and subscribers are alerted in real time — often before the change is widely reported.
Why does staying current on Pharmaceutical Manufacturing (FDA/DEA) matter?
A single missed change can mean fines, a lapsed licence, or lost eligibility. Forewarned is forearmed — knowing first lets you act before it costs you.